Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.56 |
| ▸ | CNR1 | P21554 | 6/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29122000 | 0.93 | ELANE (0.58) | ELANEALDH1A1SMN1; SMN2TSHRHTT | |
| SCHEMBL29122252 | 0.88 | ELANE (0.58) | ELANEALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL30676419 | 0.88 | ELANE (0.58) | ELANEALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL29121525 | 0.87 | ELANE (0.60) | ELANEALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL18525604 | 0.86 | ELANE (0.57) | ELANESMN1; SMN2 | |
| SCHEMBL18526221 | 0.86 | ELANE (0.52) | ELANEMAPTTSHRHTT | |
| SCHEMBL18525606 | 0.86 | ELANE (0.52) | ELANESMN1; SMN2TSHRHTT | |
| SCHEMBL29345749 | 0.83 | ELANE (0.47) | ELANECNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25930827 | 0.82 | ELANE (0.58) | ELANEMAPTTSHRHTT | |
| SCHEMBL29121991 | 0.81 | ELANE (0.57) | ELANESMN1; SMN2MAPTTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | ELANE 110/4885CNR1 4787/4885CNR2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.